z-logo
open-access-imgOpen Access
Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021
Author(s) -
Allison D. Miller,
Laura D. Zambrano,
Anna R Yousaf,
Joseph Y. Abrams,
Lu Meng,
Michael Wu,
Michael Melgar,
Matthew E. Oster,
Shana E Godfred Cato,
Ermias D. Belay,
Angela P. Campbell,
Gloria E Anyalechi,
Anna Bowen,
Tuyen Do,
Paul A. Gastañaduy,
Katherine Lindsey,
Sancta B. St. Cyr,
Ramandeep Kaur,
Xandy Peterson Pompa,
Chloe E. Le Marchand,
Jason Robert C Singson,
Shan C O’Brien,
Ann Schmitz,
Carola I Torres Díaz,
Walaa M Elbedewy,
Melissa TobinD’Angelo,
Heather D. Reid,
Marielle Fricchione,
Sara Hallyburton,
Gillian Richardson,
Julie Hand,
Dylan Leach,
Cole Burkholder,
Sarah Lim,
Deepam Thomas,
Donna L Gowie,
Elizabeth Dufort,
Ellen H. Lee,
Ayotola Falodun,
Courtney Dewart,
Zachary J Colles,
Jennifer L. Wallace,
LaKita D Johnson,
Kristina L Herring,
Andrea R Liptack
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab1007
Subject(s) - medicine , covid-19 , medline , pediatrics , virology , outbreak , infectious disease (medical specialty) , disease , political science , law
Background Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition in persons aged <21 years associated with antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to describe MIS-C cases reported to Centers for Disease Control and Prevention’s (CDC’s) national surveillance since the coronavirus disease 2019 (COVID-19) pandemic began. Methods We included patients meeting the MIS-C case definition with onset date from 19 February 2020 through 31 July 2021, using CDC’s MIS-C case report form, which collects information on demographics, clinical presentation, and laboratory results. Trends over time across 3 MIS-C pandemic waves were assessed using Cochran-Armitage test for categorical and Jonckheere-Terpstra test for continuous variables. Results Of 4901 reported cases, 4470 met inclusion criteria. Median patient age increased over time (P < .001), with a median of 9 years (interquartile range, 5–13 years) during the most recent (third) wave. Male predominance also increased (62% in third wave, P < .001). A significant (P < .001) increase in severe hematologic and gastrointestinal involvement was observed across the study period. Frequency of several cardiovascular complications (ie, cardiac dysfunction, myocarditis, and shock/vasopressor receipt) and renal failure declined (P < .001). Provision of critical care including mechanical ventilation (P < .001) and extracorporeal membrane oxygenation (ECMO; P = .046) decreased, as did duration of hospitalization and mortality (each P < .001). Conclusions Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom